Advisors Preferred’s Dr. Reddy's Laboratories RDY Stock Holding History

Advisors Preferred’s Portfolio RDY Stock Details RDY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-15,065	Closed	-$223K	–	218
2024 Q1	$223K	Sell	15,065 -3,155	-17%	-$46.1K	0.04%	115
2023 Q4	$258K	Buy	+18,220	New	+$244K	0.04%	131
2019 Q3	–	Sell	-7,125	Closed	-$55K	–	286
2019 Q2	$55K	Buy	+7,125	New	+$56K	0.02%	127

Other funds holding RDY

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

Aikya Investment Management London, United Kingdom $341M AUM 28.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Advisors Preferred's RDY Position: Q2 2024 in Review

Advisors Preferred sold out of Dr. Reddy's Laboratories (RDY) in Q2 2024, closing a stake of 15,065 shares — an estimated $223K sold.

Advisors Preferred first reported a position in RDY in Q2 2019 and held it in 3 quarters. The position peaked at $258K in Q4 2023. 222 funds tracked by Wall St. Rank hold RDY as of Q2 2024.

Advisors Preferred reported no remaining Dr. Reddy's Laboratories position as of Q2 2024 after selling out during the quarter.
Advisors Preferred sold 15,065 Dr. Reddy's Laboratories shares in Q2 2024, an estimated $223K.
Advisors Preferred first reported a position in Dr. Reddy's Laboratories in Q2 2019 and held it in 3 quarters.
Advisors Preferred's Dr. Reddy's Laboratories position peaked at $258K in Q4 2023.
222 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q2 2024.

Based on Advisors Preferred's 13F filing for Q2 2024, filed 30 Jul 2024.